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Abstract
Background: Massively parallel sequencing technologies have brought an enormous increase in sequencing
throughput. However, these technologies need to be further improved with regard to reproducibility and
applicability to clinical samples and settings.
Methods: Using identification of genetic variations in prostate cancer as an example we address three crucial
challenges in the field of targeted re-sequencing: Small nucleotide variation (SNV) detection in samples of formalin-
fixed paraffin embedded (FFPE) tissue material, minimal amount of input sample and sampling in view of tissue
heterogeneity.
Results: We show that FFPE tissue material can supplement for fresh frozen tissues for the detection of SNVs and
that solution-based enrichment experiments can be accomplished with small amounts of DNA with only minimal
effects on enrichment uniformity and data variance.
Finally, we address the question whether the heterogeneity of a tumor is reflected by different genetic alterations,
e.g. different foci of a tumor display different genomic patterns. We show that the tumor heterogeneity plays an
important role for the detection of copy number variations.
Conclusions: The application of high throughput sequencing technologies in cancer genomics opens up a new
dimension for the identification of disease mechanisms. In particular the ability to use small amounts of FFPE
samples available from surgical tumor resections and histopathological examinations facilitates the collection of
precious tissue materials. However, care needs to be taken in regard to the locations of the biopsies, which can
have an influence on the prediction of copy number variations. Bearing these technological challenges in mind will
significantly improve many large-scale sequencing studies and will - in the long term - result in a more reliable
prediction of individual cancer therapies.
Background
According to the world health organization (WHO)
malignant neoplasms are the most common cause of
death worldwide in 2010 [1]. We now know that human
solid tumors, which account for the majority of all
human cancers, result from the accumulation of
numerous genetic and epigenetic alterations that finally
lead to the deregulation of protein-encoding genes
[2-10].
Previous efforts to identify protein-encoding cancer
genes were limited by insufficient technologies to detect
genomic alterations on a global scale. Over the last
years more advanced technologies such as next genera-
tion sequencing (NGS) technologies have been devel-
oped to detect the various patterns of mutations and
rearrangements in individual cancer genomes revealing
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nologies promise to bring about a revolution in cancer
genomics such that it becomes feasible to describe the
complex genetic networks underlying tumors and thus
to identify pathomechanisms of tumor progression and
therapy resistance [12-16].
In this regard first whole genome sequences have been
published. For example, sequencing of a cytogenetically
normal acute myeloid leukemia genome has revealed
eight somatic mutations [14]. Within a similar range is
the profile of a sequenced breast tumor with 32 non-
synonymous somatic mutations [15]. Recently the com-
plete genomes of lung cancer and melanoma cell lines
have been analyzed and indicate correlations between
DNA repair mechanisms and mutational spectra [17,18].
However, even though the power of next generation
sequencing (NGS) technologies is enormous, remarkably
few studies on cancer genomes have been published so
far. This is mainly due to the fact that NGS is still rela-
tively cost - and time - intensive and that bioinformatics
analyses of tumor tissues are not only challenging, but
a l s on e e dal o to ft i m e-t h i si sl i k e l yt ob et h em a j o r
bottleneck in the future. One solution to these draw-
backs is to increase the sequencing output by focusing
on coding DNA regions [11,19,20]. Several targeted
DNA enrichment technologies to reduce sequence com-
plexity are available [21-27]. These technologies have
been mainly developed using large amounts of input
DNA generated from blood samples. To identify somatic
mutations in solid tumors,D N Ah a st ob ee x t r a c t e d
from tissues; with often limited access and amounts of
extracted DNA. Formalin fixed and paraffin embedded
(FFPE) tissue samples, which are archived on a routine
basis in pathology departments, could render more and
rare conditions accessible. Although FFPE tissue was
successfully used for low-coverage whole genome
sequencing and copy number detection it is not known
if it can be taken for SNV and InDel detection after tar-
geted enrichment strategies [28].
Here, we have specifically addressed cancer-relevant
technical questions for targeted sequencing in cancer
genomics. We investigated whether FFPE tissue mate-
rial can be used for targeted re-sequencing applica-
tions. We further evaluated the reproducibility and
uniformity of the experiments and the effect of modifi-
cations such as DNA input amounts. Finally we
addressed the question whether the heterogeneity of
the tumor as seen by a pathologist is reflected by dif-
ferent mutation patterns or copy number alterations, e.
g. if the localization of the biopsy matters. For this, we
established quality standards for targeted re-sequencing
experiments which can be also used for round-robin
tests in clinical diagnostics.
Methods
Prostate tissue collection and preparation
Frozen and paraffin-embedded prostate tissue samples
were obtained from five patients who had undergone
radical prostatectomy at the Department of Urology,
Innsbruck Medical University [29,30]. Immediately after
surgery, the prostate specimens were cooled and sent to
the pathologist, who performed a rapid section and iso-
lated a prostate slice that was embedded in Tissue-Tek
OCT Compound (Sakura Finetek, Staufen, Germany),
snap-frozen in liquid nitrogen, and stored at -80°C until
use. Pathological and clinical data were retrieved from
the clinical databases and patients health records. The
study was approved by the ethics committee at the
Innsbruck Medical University and is in compliance with
the Helsinki Declaration (UN3174 and AM3174).
Isolation of DNA samples from prostate tissues
DNA samples were isolated from radical prostatectomy
specimens of five patients. For isolation of DNA, 3 μm
sections of the frozen specimens were prepared and
stained with hematoxylin and eosin for pathological ana-
lysis and exact localization of the tumors. For each
tumor sample, a paired benign (histopathologically nor-
mal) counterpart region distant from the tumor focus
was identified. Selection of different foci was based on
differences of histological and morphological phenotypes
and was performed and controlled on the basis of HE
stainings and P63/AMACR double immunostainings.
P63 as a basal epithelial cell marker is absent in tumors,
and tumor cells are positive for AMACR. In each case
the two markers displayed different histopathological
gradings, in two cases Gleason patterns 3+4 in the low
grade focus and 4+5 in the high grade focus, the third
case displayed an additional tertiary pattern 5 in the
high grade focus. Subsequently, depending on the tumor
area, 5-10 consecutive 10 μm sections were cut and
carefully macro-dissected for isolation of tumor and
benign regions, and the tissue pieces were collected in
pre-cooled DNase/RNase free 1.7 ml micro-centrifuge
tubes (Costar, Corning, MA, USA). The number of con-
secutive slides used for macrodissection was adjusted in
each case to approximately 5-10 cm
2 of overall tissue
section, which corresponds to approximately 5-10 mg of
tissue and yielded between 2 and 9 μgo fD N A .F o r
DNA isolation, the EZ1 DNA tissue kit (Qiagen, Hilden,
Germany) was used and the isolation was performed
according to the protocol recommended by the supplier
on a BioRobot EZ1 (Qiagen) equipped with the EZ1 tis-
sue card. To increase DNA yield, the solubilization buf-
fer was supplemented with additional 40 μlo f
Proteinase K solution (Roche, Basel Switzerland) and
protease digestion was carried out over night at 56°C
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tion. After sample isolation the DNA amount was deter-
mined by UV spectroscopy using a Nanodrop
instrument (PEQLAB Biotechnology, Erlangen Ger-
many) and the quality was assessed by calculating the
A260/280 ratio, which had to be ≥1.8.
For isolation of DNA from paraffin-embedded tissue
specimens the EZ1 DNA tissue kit (Qiagen) procedure
was slightly modified. Combined sections of each sample
were suspended in 200 μl of sample extraction buffer
G2. Samples were incubated for 5 min at 75°C with vig-
orous mixing (1400 rpm) on a thermomixer (Eppen-
dorf). Thereafter the incubation temperature was
lowered to 56°C and 10 μlo fp r o t e a s eKs o l u t i o n
(Roche) were added. Incubation at 56°C with continuous
shaking was continued for an hour. During that hour
samples were suspended 2-3 times by pipetting up and
down several times to facilitate dissolution of the tissue
samples. Afterwards additional 40 μl of protease K solu-
tion were added and the incubation at 56°C was contin-
ued over night. On the next morning additional 20 μlo f
protease solution was added and the incubation with
shaking continued for 1 hour. Then the samples were
centrifuged in a table centrifuge (Eppendorf) at 10000 g
for 1 min to pellet all insoluble material and the super-
natant was transferred to a fresh 2 ml sample tube.
DNA was isolated with an EZ1 BioRobot (Qiagen)
equipped with an EZ1 DNA Paraffin Section Card using
the EZ1 DNA Tissue Kit according to the instructions
for this instrument. At the end of the purification proce-
dure the DNA was eluted in 50 μl of RNAse/DNAse
free water and the DNA concentration was measured
using a nanodrop photometer (Peqlab, Erlangen
Germany).
DNA capturing of selected regions (3.9 Mb and 52 Mb)
The library preparation was performed according to
Agilent’s SureSelect protocol for Illumina single end
sequencing with slight modifications. In brief, 0.5-3.0 μg
of genomic DNA was sheared for 90 sec on a Covaris™
instrument set (duty cycle 20%, intensity 5 and 200
cycles per burst). The fragmented DNA (200-300 bp)
was re-quantified with the Agilent 2100 Bioanalyzer
7500 chip. The following end repair reaction was per-
formed to generate blunt-end fragments with 5’-phos-
phorylated ends. For the adapter ligation the “A” bases
were added to the 3’-end of the DNA fragment. The
adapters (5’GATCGGAAGAGCTCGTATGCCGTCTT
CTGCTTG3’)a n d( 5 ’ACACTCTTTCCCTA-CAC-
GACGCTCTTCCGATCT3’)w e r eu s e di na1 0 : 1m o l a r
ratio to raw genomic DNA.
The ligation products were purified and size selected
with a range of 200-350 bp by agarose gel electrophor-
esis at 120 V for 1 h. The amplification of the library
was performed with the Phusion High-Fidelity PCR
master mix with HF buffer (Finnzymes) using Illumina
PCR primers 1.1
(5’AATGATACGGCGACCACCGAGATCTACACT
CTTTCCCTACACGACGCTTCCGATCT3’)a n d2 . 1
(5’CAA-GCAGAAGACGGCATACGAGCTCTTCCG
ATCT3’) for 14 cycles.
For the hybrid selection the libraries were adjusted
to 500 ng in 3.4 μlH 2Oa n da d d e dt ot h eS u r e S e l e c t
Block solutions. This mixture was heated at 95°C for
5 min and held for 5 min at 65°C. The library was
then mixed with the prewarmed hybridization buffer
(5 min at 65°C) and SureSelect oligo capture library
mix (2 min at 65°C). After 24 h incubation at 65°C,
the hybridization mix was added to 500 ng (50 μl) of
M-280 streptavidin Dynabeads (Invitrogen), and the
incubation was continued for 30 min at room tem-
perature (RT). The beads were pulled down and
washed once at RT for 15 min with 500 μl of SureSe-
lect wash buffer 1, followed by three 10 min washes at
65°C with 500 μl of prewarmed SureSelect wash buffer
2. Hybrid-selected DNA was eluted with 50 μl of Elu-
tion buffer and incubated for 10 min at RT. After the
pull down of the beads, the supernatant was trans-
ferred to a tube containing 50 μl of Neutralization
buffer and the samples were desalted and concen-
trated on a QIAquick MinElute column and subse-
quently eluted in 30 μl Elution buffer. The post
amplification step was performed with the Herculase
polymerase and the SureSelect GA PCR-Primer-mix
for 14 cycles.
Quality control and NGS Sequencing
Quantification of the SureSelect captured library: Before
sequencing, the samples were re-quantified with two
methods. First, the size and concentration was checked
on the Agilent 2100 Bioanalyzer and in a second step
the enrichment efficiency was estimated by qPCR
(Applied Biosystems) using a primerset for an enriched
exon (fw: ATCCCGGTTGTTCTTCTGTG and rv:
TTCTGGCTCTGCTGTAGGAAG) and a primerset in
an intron region as a negative control (fw: AGGTTT
GCTGAGGAACCTTGA and rv: ACCGAAACATCCT
GGCTACAG). In general the CT-values of target and
control fragments differed by 6 to 10, thus confirming a
very good enrichment of our target regions.
After diluting the captured libraries to 10 nM, Gen-
ome Analyzer single read flow cells were prepared on
the supplied Illumina cluster station and 36 bp single
end reads on the Illumina Genome Analyzer IIx plat-
form were generated following the manufacturer’sp r o -
tocol. Images from the instrument were processed using
the manufacturer’s software to generate FASTQ
sequence files.
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Cryo-embedded tissue material was genotyped on the
Affymetrix 6.0 array, according to the manufacturer’s
protocol. Array positions with a quality score (p-value)
< 0.01 were used as a ‘gold standard’ for the comparison
with the sequencing data. Sequencing data positions
within the enriched regions were used if their coverage
exceeded 3-fold. This generated 6, 127 and 6, 122 posi-
tions for cryo and FFPE tissue, respectively, that were
eligible for comparison. To determine false positive and
false negative rates, we set the array data as standard
and distinguished between reference call and SNP call
depending on the array data.
Bioinformatics analyses
Alignment: Raw reads were mapped to the golden path
version hg19 using the bwa 0.5.8 alignment tool with
default parameters. Sequences were deposited at the
European Genome-phenome Archive [EGA:
EGAS00001000136]. Enrichment statistics were calcu-
lated for target regions extended by 100 bp on either
side. A read had to have at least one base within the tar-
get region to be evaluated “on target”.
Coverage uniformity: The coefficient of variation was
calculated for normalized mean coverages per exon.
Normalization was done by a fixed factor per tissue
sample to adjust the median coverage over all exons to
the same level across all samples. For each two way
comparison per exon we plotted the mean coverage of
the exon with lower coverage on the x-axis. To examine
the GC content dependent coverage for FFPE prepara-
tions for all exons the GC content was counted and
exons were combined according to their GC content in
step sizes of 0.1%. The basewise average exon coverage
was averaged within each bin.
Normalized coverage-distribution plots were calcu-
lated as follows: The mean coverage per exon was
divided by the overall mean coverage of all exons as
normalized coverage (x-axis). The fraction of bait-cov-
ered exons in the genome achieving coverages equal or
lower than the overall mean coverage is indicated on
the y-axis.
Sorted coverage plots: Exons were sorted by their
mean coverage and plotted along the x-axis. Coverage
was plotted on the y-axis using a log10 scale.
Variant detection and comparison: Initial SNV and
InDel detection was done using samtools 0.1.8 for each
sample separately. Detected SNVs were required to have
a Phred-scaled SNV probability greater or equal 20 and
the SNV had to be present in at least 15% of all reads at
a given position. A two step procedure was then applied
to call the SNVs for comparison. SNVs detected by our
criteria in one preparation were then examined in the
second preparation to see if the SNV was found in at
least one read. Discordant positions were determined by
complimentary comparisons: SNVs called in preparation
A had not to be found in preparation B or vice versa.
Divergent positions for the snap frozen versus FFPE
comparison could be stratified into false positive and
false negative, assuming the snap frozen preparation as
reference. For somatic SNV detection from two biopsies
of the same prostate cancer tumor the Phred-scale cut-
off was required to be greater or equal to 20 and the
SNV was required to be found in both tumor foci in at
least 4 reads but not in the corresponding benign tissue
with a minimal coverage of 10 fold.
Determination of copy number variations
After the DNA fragments were mapped aligned DNA
read frequencies were determined for chromosomal
intervals (bins) of 55-190 Kb. Interval sizes were chosen
individually for each chromosome so that a minimal
count of 600 reads per bin was achieved to ensure even
data variance across the genome. The log2 ratio of
tumor versus benign counts per bin was calculated and
normalized by setting the genome wide median of the
ratios to zero. To visualize copy number changes we cal-
culated a running median of 20 bins using the lowess
function in R. Differences in copy number between the
two foci of one tumor were visualized by calculating the
difference of the two running median vectors. Differ-
ences greater or equal 0.2 were highlighted.
Results
FFPE tissue can be used for targeted DNA capturing
experiments and SNV detection
Thousands of patient samples are stored in pathology
departments as formalin fixed and paraffin embedded
(FFPE) tissues and provide an excellent source for mole-
cular genetic studies. Previously we have shown that
whole genome sequencing can be performed with this
material [28,31].
Since many large-scale sequencing projects are now
directed towards exome sequencing strategies, the ques-
tion remains whether targeted re-sequencing on FFPE
tissue might be possible. We therefore divided prostate
tissue samples of radical prostatectomy specimens and
stored one part as snap frozen tissue blocks, the other
as FFPE material (Figure 1, Additional file 1, Methods).
We used material from both preservation technologies
for DNA extraction and subsequent hybridization for
DNA capturing followed by Illumina sequencing of the
“whole Exome” target region (52 Mb) as well as for a
3.9 Mb custom designed target region (Table 1 Addi-
tional file 2, Table S1). One caveat of next generation
sequencing protocols from FFPE material is the high
temperature (above 90°C) needed to melt the paraffin,
which results in a significant fraction of single stranded
Kerick et al. BMC Medical Genomics 2011, 4:68
http://www.biomedcentral.com/1755-8794/4/68
Page 4 of 13DNA. However, for the subsequent library preparation
step double stranded DNA is required. We found that
an initial heating step to 75°C for 5 min is sufficient to
melt the paraffin and preserve dsDNA. (Detailed proto-
cols for the preparation of DNA, libraries and the cap-
turing are provided in the Material and Method
section.) For both DNA materials - snap frozen as well
as FFPE stored - we identified an average of 75% of the
sequencing reads located within the whole exome target
region and more than 99% of the regions were captured
by at least one read (Table 1, Additional file 2, Table
S3). Both preservation technologies have similar cover-
age profiles and we found a high degree of correlation
of enrichment per exon between experiments, which is
depicted as coefficient of variation (Figure 1A, Addi-
tional file 1 Figure S1A, B). Even though the coefficient
of variation is low within the same preparation technol-
ogy, e.g. snap frozen versus snap frozen and FFPE versus
FFPE, the variation is higher between snap frozen and
FFPE. Thus, one should preferably remain within the
same tissue preparation technology for one set of
experiments (Additional file 1, Figure S1C). It is known
that FFPE tissues are prone to spontaneous deamination
of guanine and cytosine during the tissue preservation
process and/or during storage and that the Illumina
sequencing technology is biased for underrepresentation
and reduced quality at loci with extreme base composi-
tions [32]. In this regard, we found a slight, but not sig-
nificant, shift in the GC-dependent coverage profile
between the snap-frozen and FFPE tissue (Figure 1B,
Additional file 1, Figure S1D).
To assess the effect of coverage depth on the sensitivity
and specificity of sequence variant detection, we used
genotype calls of an Affymetrix SNP array 6.0 from the
cryo material and compared each position to the whole
exome sequencing data. For both tissue preparations we
Figure 1 Comparison of FFPE and snap frozen tissue material for whole exome re-sequencing approaches.( A)E x o n w i s ec o v e r a g e
comparison of snap frozen and FFPE DNA preparations for a benign tissue sample. Coefficients of variation are calculated exonwise and plotted
by the smallest coverage of each exon-exon comparison. As reference, coefficients of variation were calculated for two sequencing replicates of
the snap frozen preparation (B) Mean coverage by GC content for snap frozen and FFPE DNA preparations. All exons were split into 800 bins by
GC content and the average exon coverage was averaged within each bin. (C) Comparison of SNVs and InDels detected in snap frozen and
FFPE DNA preparations for a benign tissue sample. False negative SNVs/InDels are detected in the snap frozen preparation but not in the FFPE
preparation. False positive SNVs/InDels are detected in the FFPE preparation but not in the snap frozen preparation. (D) Comparison of SNVs
detected in snap frozen and FFPE DNA preparations with Affymetrix SNP array 6.0 plotted by minimal coverage.
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erages down to 10× (Figure 1D).
Next we investigated the reproducibility of single
nucleotide variation (SNV) detection in snap frozen ver-
sus FFPE tissues. We found 179 (1.2%) discordant loci
investigating positions with at least 20-fold coverage.
The potential artifacts can be grouped into false posi-
tives, e.g. a SNV is found in FFPE tissue without evi-
dence in snap frozen tissue and false negative SNVs,
w h e r eaS N Vi sf o u n di ns n a pf r o z e nb u tn o ti nF F P E
material. Of the discordant loci we found 149 (0.99%)
potential false positives with all but four that can be
explained by processes likely to occur during formalin
fixation, as e.g. deamination (C > T, A > G, 76 Loci,
53%). As false negative SNVs, namely SNVs found in
snap frozen preparations but not FFPE preparations, we
found 30 loci (0.2%) at a coverage level of greater than
20×. We next addressed the question if the differences
detected can be overcome using more stringent coverage
cutoffs (Figure 1C). While at 40× coverage 12 (0.19%)
discordant loci were found, no discordance is left at 80×
coverage. This also holds true for the custom designed
sequencing of a 3.9 Mb region in tumor tissues (Addi-
tional file 1, Figure S1E).
In addition to SNVs we also detected insertions and
deletions (InDels) and compared InDels detected in snap
frozen versus FFPE tissues at a coverage cutoff of 20×.
Discordant positions were found more frequent for
InDels as opposed to SNVs with 8 (1.17%) loci as false
positive and 4 (0.58%) loci as false negative positions.
Again, higher coverage levels led to a lower percentage of
discordant InDels, with no differences found at a cover-
age level of 40× (Figure 1C, Additional file 1, Figure 1F).
Targeted sequence enrichment for small amounts of
input DNA
An important objective of technology development is to
lower the amount of input DNA required. To this end,
we used the targeted enrichment of 3.9 Mb distributed
over 12, 366 independent regions and performed enrich-
ment experiments with three different amounts of DNA
(500 ng, 1500 ng, 3000 ng) obtained from frozen prostate
cancer tissues. We found the enrichment efficiency to be
similar for all three DNA amounts: Approximately 80%
of sequencing reads mapped to the target regions and
more than 98% of targets were hit at least once (Table 1,
Additional file 2, Table S3). All three preparations had
very similar global coverage profiles. In addition we
found a high degree of correlation of enrichment per
exon between experiments with a coefficient of variation
lower than 0.2 at 20× coverage for all comparisons made
(Figure 2A, Additional file 1, Figure S2). The enrichment
is highly uniform and reproducible across several experi-
ments (Additional file 1, Figure S2, S3).
Since smaller amounts of DNA might lead to a
decreased sample complexity, and thereby to increased
data variance, we calculated and visualized the variant/
reference ratio distributions for different DNA
Table 1 Sequencing statistics
ID sample specification Target size # uniquely aligned reads % reads on target # of enriched regions # of SNVs called (20×)
Pat1_B Snap-frozen 52 Mb 66, 114, 467 75.4% 200, 175 18, 287
Pat1_B FFPE 52 Mb 71, 590, 872 74.7% 200, 032 17, 810
Pat11_B Snap-frozen 3.9 Mb 28, 043, 981 62.8% 12, 274 3, 000
Pat11_T Snap-frozen 3.9 Mb 18, 302, 565 71.3% 12, 226 2, 511
Pat11_B FFPE 3.9 Mb 9, 311, 629 67.1% 12, 175 2, 577
Pat11_T FFPE 3.9 Mb 15, 928, 525 73.7% 12, 254 2, 883
Pat2_T 500 ng 3.9 Mb 8, 760, 773 81.1% 12, 220 2, 652
Pat2_T 1500 ng 3.9 Mb 9, 686, 320 79.9% 12, 243 2, 848
Pat2_T 3000 ng 3.9 Mb 6, 810, 410 80.4% 12, 204 2, 602
Pat3_B Benign tissue 3.9 Mb 19, 617, 926 67.7% 12, 122 2, 002
Pat3_T Focus-1 3.9 Mb 28, 798, 280 68.9% 12, 227 2, 328
Pat3_T Focus-2 3.9 Mb 31, 939, 154 69.6% 11, 142 2, 513
Pat4_B Benign tissue 3.9 Mb 8, 878, 742 66.2% 12, 281 2, 662
Pat4_T Focus-1 3.9 Mb 8, 768, 332 64.2% 12, 288 2, 645
Pat4_T Focus-2 3.9 Mb 9, 178, 790 65.3% 12, 269 2, 706
Pat5_B Benign tissue 3.9 Mb 25, 957, 461 63.2% 12, 274 2, 646
Pat5_T Focus-1 3.9 Mb 65, 372, 578 64.4% 12, 261 2, 388
Pat5_T Focus-2 3.9 Mb 25, 957, 461 63.0% 11, 157 2, 342
ID: Identification number of the patient’s tissue with B for benign tissue and T for tumor tissue.
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InDels (Figure 2B). In an ideal situation a heterozygous
position would have 50% reads showing the variant - a
variant/reference ratio of 0.5. Based on the ratios we
find a slightly broader distribution for small amounts
of input DNA which is also shifted towards higher
ratios. The slightly lowered complexity of the samples
with decreased DNA input amounts is also reflected in
the number of unique start sites: For 500 ng input
material we received 40% of the expected unique start
sites (calculated in relation to the 3.9 Mb target
region), for 1500 ng 54% and for 3000 ng 62%. This
needs to be considered when the input amounts are
reduced and when homozygous versus heterozygous
gene loci are compared. In comparison to SNV call-
ings, InDels do not follow the expected bimodal distri-
bution for variant/reference ratios but resemble rather
a Bernoulli distribution (Figure 2B). Based on these
findings, we chose to discard InDels with variant/refer-
ence ratios lower than 15% from further analysis.
For the SNVs and InDel detection we next asked how
reproducible they are and how high the coverage needs
to be to minimize the error rates. Since all three pre-
parations originated from the same tumor DNA and
only the amount of input DNA differed, identical SNVs
and InDels should be called. We therefore investigated
if SNVs and InDels called for each amount of DNA
were found in the other preparations with different
amounts of DNA. With a minimum coverage of 3×, we
found more than 98% concordance between two sam-
ples for SNVs (Figure 2C). Interestingly, when we
looked at SNVs, which had been already annotated in
the dbSNP database (referred to as ‘known SNVs’), the
concordance rates are even higher reaching about 99%
at 3× coverage. In contrast, when we looked at SNVs
which had not been annotated so far (’unknown SNVs’),
concordance rates below 55fold coverages were up to
30% lower than for ‘known’ loci (Additional file 1, Fig-
ure S4). At coverage rates of 55× or more, SNV concor-
dances were higher than 98% for ‘known’ and ‘unknown’
Figure 2 Different DNA amounts for targeted re-sequencing approaches.( A) Exonwise coverage comparisons obtained with different
amounts of input DNA. Coefficient of variations were calculated for each comparison and plotted by the smallest coverage of each exon-exon
comparison. (B) Variant/Reference ratio distribution for different amounts of input DNA. Depicted is the density curve for each preparation and
distribution. (C) Comparison of SNVs detected with different amounts of input DNA. The Y-axis depicts the percentage of foci in concordance for
different preparations at different coverage levels. (D) Comparison of InDels detected with different amounts of input DNA. The y-axis depicts
the percentage of foci in concordance for different preparations at different coverage levels.
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Page 7 of 13loci alike. For InDels we found concordance rates of
98% at above 20× coverage (Figure 2D), and we
observed much smaller differences between known and
unknown positions (Additional file 1, Figure S5).
Distinct biopsies from a single tumor have identical
somatic SNV profiles in selected prostate cancer
candidate genes, but differ in their copy number patterns
A long-standing question of cancer research is whether
biopsies are true representatives for the tissue of origin.
This is of particular interest since many solid tumors
grow as distinct tumor foci. We therefore addressed the
questions whether biopsies from prostate tumors are
uniform or if they are associated with different muta-
tional patterns or different copy number variations.
Prostate cancer is a prototype tumor to address this
problem. The majority of these tumors are multifocal
and in many cases two or more distinct, locally sepa-
rated tumor foci can be identified [30,33].
We designed a target gene set of 1121 genes carefully
selected by association to prostate cancer, cancer in gen-
eral and signal transduction pathways. DNA was isolated
from two different loci for each tumor in addition to
matched benign tissue from frozen radical prostatect-
omy specimens of three prostate cancer patients. Selec-
tion of different foci was based on differences of
histological and morphological phenotypes and was per-
formed and controlled on the basis of HE stainings and
P63/AMACR double immunostainings. The basal cell
marker P63 decorates only benign glands whereas
AMACR is a marker for tumor cells. In each case the
two tumor foci analyzed displayed different histopatho-
logical gradings, in two cases Gleason patterns 3+4 in
the low grade focus and 4+5 in the high grade focus,
the third case displayed an additional tertiary pattern 5
in the high grade focus (See also Table 2 and Additional
file 1, Methods).
Targeted enrichment with subsequent sequencing was
performed with these nine tissue samples. We found the
enrichment efficiency to be very similar for all samples:
Approximately 69% of sequencing reads mapped to the
target region and about 99% of targets were hit at least
once (Table 1 and Additional file 2, Table S3). In addi-
tion, the coverage profiles were very similar for all
patients as demonstrated by the cumulative normalized
coverage plot and the coefficients of variation (Figure
3A, B).
For a comparison of the SNV profiles we used a two
step procedure for loci covered in both preparations at a
minimal coverage level of 20×. First, called SNVs for
focus A were required to have at least 15% of reads con-
taining the SNV. In the second step focus B was then
analyzed and a SNV was considered concordant if the
SNV was found in at least one read of focus B.
Although the SNVs differed substantially between
patients, we found no discordant position in any two
foci of the same tumor in the three patients at this level
of stringency. We also determined the concordance of
SNV profiles at smaller coverage levels (Figure 3C). At a
minimal coverage of 5× we observed 0.4% discordant
loci at maximum but this difference is most likely
caused by an amplification bias rather than by real dif-
ferences, since the number of discordant foci quickly
diminishes with rising coverage demands. We analyzed
small InDels in a similar way and found again higher
rates of discordance as compared to SNVs (Figure 3D).
Except for one discordant locus found in Patient 5, no
discordances were found when higher coverage cutoffs
were used. We also investigated potential somatic SNVs
by comparing each individual focus with its matched
benign tissue. We found one somatic SNV for each of
the three patients. This mutation was identified in both
tumor foci but not in the benign tissue (Table 2).
In addition to the SNV profiles for the different tumor
foci we also investigated the copy number variations
within each focus. For this, we generated low-coverage
whole genome sequencing profiles for the two tumor
foci and the corresponding benign tissue from each
patient. We determined potential somatic copy number
variations by comparing each tumor focus with the
matched benign tissue (Additional file 1, Figure S6).
Received copy number variations were then compared
between the two foci and the difference was plotted
genome-wide (Figure 4). For patient 3 we found clear
differences on chromosome 4, 10 and 13 between both
foci with regard to CNVs (Additional file 1, Figure S6
Table 2 TMPRSS-ERG Fusion status and somatic
mutations of the different foci analysed
patient-ID Gleason
Score
TMPRSS2-ERG
Fusion
somatic
substitutions
Pat3_
normal
Pat3_Focus
1
4+5 Deletion SH3BGR
chr21:40883678
Pat3_Focus
2
3+4 no Fusion
Pat4_
normal
Pat4_Focus
1
3+4 no Fusion SH3BGR
chr21:40883671
Pat4_Focus
2
3+4(5) no Fusion
Pat5_
normal
Pat5_Focus
1
3+4 no Fusion NUB1
chr7:151053043
Pat5_Focus
2
4+5 Deletion and
Insertion
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Page 8 of 13A-C). In comparison, the biopsies taken from patient 4
and 5 seemed more homogeneous as no differences of
the CNV profiles were apparent between the two tumor
foci. Marked differences for patient 5 are located
towards chromosome ends and visual inspection pro-
posed the individual CNVs to be artefacts (Additional
file 1, Figure S6 D).
Discussion
Next-generation technologies such as targeted re-
sequencing platforms are powerful tools for identifying
genetic variations in cancer samples. Using prostate can-
cer as an example, we have assessed the use of different
kinds and amounts of tissue samples for identifying
genetic variations. In particular, we have investigated
t h r e ea s p e c t sw h i c ha r ef r e q u e n t l ya d d r e s s e df r o m
oncologists and pathologists:
The first is whether or not it is possible to use FFPE
material in addition to snap frozen material. The use
of FFPE material would open up a large collection of
tissue samples for molecular studies since most of the
materials stored at pathology departments around the
world are archived in this way. However, the prepara-
tion procedure of FFPE tissue with formaldehyde fixa-
tion and long-term storage at room temperature may
generate DNA mutations and result in the identifica-
tion of false SNVs or InDels. We previously showed
that it is possible to use FFPE material for copy num-
ber analysis of whole genome data, although a higher
sequencing capacity is required to achieve a compar-
able coverage [28]. Now we have extended our studies
to targeted enrichment methods and found an uniform
enrichment irrespective of the kind of tissue material
used. Looking at the numbers of SNVs detected we
found 0.98% false positive SNVs in FFPE preparations
at a coverage level of 20× which can be strongly
reduced at higher coverages (> 80×). Potential false
positive SNVs can be explained by processes likely to
occur during formalin fixation, like deamination and
depurination processes. Our data suggests that the
Figure 3 Comparison of different tumor biopsies for targeted re-sequencing approaches.( A) Normalized coverage-distribution plot for
two foci of each of three tumor tissues. The mean coverage per exon was divided by the overall mean coverage of all exons and plotted as
normalized coverage (x-axis). The fraction of bait-covered exons in the genome achieving coverages equal or lower than the overall mean
coverage is indicated on the y-axis. (B) Exonwise coverage comparison of two foci of each of three tumor tissues. A coefficient of variation is
calculated for each comparison and plotted by the smallest coverage of each exon-exon comparison. (C) Comparison of SNVs detected in two
foci of each of three tumors. Discordant SNVs are those detected in focus A but not focus B and vice versa. (D) Comparison of InDels detected
in two foci of each of three tumors. Discordant InDels are those detected in focus A but not focus B and vice versa.
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Page 9 of 13damage done by the FFPE preparation has a random
distribution across all DNA fragments and can be cor-
rected by sequencing depth. Since coverage levels of
80× and higher can easily be reached by targeted re-
sequencing approaches, we recommend to use such
high coverages when analyzing FFPE material. The
same holds true for false negative SNVs. Keeping in
mind that SNV detection is the main focus of DNA
sequence analysis in cancer, the detection of small
insertions and deletions becomes increasingly impor-
tant. We therefore investigated if preparation of DNA
from FFPE tissue may have an adverse effect on InDel
detection. While the relative amount of discordant
InDel positions is about 7 times higher than the
amount of discordant SNV positions, we observed the
same low discrepancy rates at higher coverage levels.
Again, no discordance was found at a coverage level of
80×. Taken together, snap frozen tissues remain the
preferred source of DNA, but FFPE tissue can be used
for SNV and InDel detection instead if the coverage is
increased. Furthermore, for certain clinically relevant
questions, like for the detection of germline variants,
e.g. when for a snap frozen tumor tissue no adequate
matching benign tissue material is available, FFPE tis-
sues can be used. In this case, the positive error rate
obtained with FFPE material plays an inferior role.
The second methodological issue relates to the
amount of material required. Decreasing the input
amount of DNA to 500 ng still yielded good enrichment
results, an even coverage and a highly reproducible call-
ing of known genetic variants. However, we find
increased redundant reads (reads with identical first
positions) and a slightly higher variance of variant/refer-
ence ratios with decreased amounts of starting material.
This suggests that - with these enrichment technologies
- the minimal amount of input DNA cannot easily be
reduced beyond 500 ng. Notably, the comparison among
average and high amounts of DNA (1.5 μgv s3μg) per-
formed better than a comparison including the lowest
amount of DNA (500 ng).
Figure 4 Comparison of copy number profiles of different tumor biopsies. DNA read frequencies and subsequent normalized log ratios for
tumor versus normal were determined for chromosomal intervals (bins) of 55-190 Kb. Copy number changes were calculated as running median
of the log ratios of 20 bins. Differences in copy number between the two foci of one tumor are depicted as the difference of the two running
median vectors. Differences greater or equal 0.2 were highlighted in magenta.
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distribution clearly deviating from the expected bimodal
distribution and visible differences for the three DNA
amounts, InDels are still highly reproducible above a
coverage level of 45× for all amounts of DNA. We con-
clude that a decrease to 500 ng of input DNA is possi-
ble, but the benefit has to be weighed against the high
coverage demands and potential challenges to SNV and
InDel categorization.
The third challenge presented in our study consists of
the heterogeneity of tumor tissue. In order to obtain
results representative for the whole tumor, the amount
and location of biopsies necessary is unknown. So far, it
is not decided whether primary prostate cancers have a
multifocal origin and thus are composed of multiple
genetically distinct cancer cell clones or not. Currently,
an independent clonal nature of multiple foci is consid-
ered since healthy men below 40 years frequently show
presence of focal histological aberrations [34-36] many
of which give rise only to latent prostate cancer, while
clonal evolution of a few foci paves the way to clinically
detectable disease [33,37-40]. On the other hand, pros-
tate cancer metastases from different locations but from
the same patient show a surprisingly similar pattern
with regard to copy number alterations [41-43]. Experi-
ments available to address this question include the
determination of the DNA ploidy, micro-satellite analy-
sis, c-myc amplifications with FISH, DNA methylation
or the TMPRSS2-ERG fusion status on separate tumors
within the same prostate [44]. In our hands, using sam-
ples derived from different foci within one prostate
tumor and performing DNA re-sequencings of prostate
cancer relevant genes, we found almost identical distri-
butions of mutations within different foci of the same
patient. Notably, SNV profile concordance was 100% for
all three patients at coverage levels above 20×. Even
tumor parts with different TMPRSS2-ERG gene fusion
status are remarkably identical with regard to small
nuclear variations. In addition, focusing on somatic
mutations, we find no differences between different
tumor foci. However, although we focused on prostate
cancer candidate genes, the low number of somatic
mutations in prostate cancer and the fact that we only
analyzed ~10% of the exome prohibit a generalized con-
clusion. Recent studies, such as Taylor et al with 0.31,
K a ne ta lw i t h0 . 3 3 ,a n dB e r g e re ta lw i t h0 . 9n o n -
synonymous mutations per Mb, suggest low somatic
mutation rates per Mb for prostate cancer [8,9,45]. In
line with this somatic mutat i o nf r e q u e n c yw ef o u n d
only one somatic mutation for each of the three
patients. The sensitivity of current re-sequencing
approaches might further explain the missing focal
diversity. Irrespective of the low frequency of somatic
mutations we detected in the tumor samples we found
large aberrations in copy number. We have used a
whole genome re-sequencing approach to detect somatic
copy number variations for each focus and compared
the two foci from the same tumor. Interestingly, for one
patient with clear differences in the TMPRSS2-ERG
fusion pattern, we also find significant differences
between the two foci, whereas for two other patients no
significant CNVs can be detected. Along this line Navin
et al. used a modified comparative genomic hybridiza-
tion (CGH) technology to study the clonal composition
of breast tumors and found a large proportion of mono-
genomic tumors and only a small fraction of tumors
with a heterogenomic foci structure [46]. Our results
would implicate that the location of biopsies taken
within tumors is of minor relevance for the detection of
mutations, but plays a major role for the detection of
copy number variations. Within this direction, recent
publications also suggest that genomic rearrangements
are a major genetic factor underlying prostate cancer
[47]. Since we did not perform 3D reconstructions of
the whole tumors our approach cannot be used to
answer the question of multifocal origin of heteroge-
neous prostate tumors. Even for the estimation of tumor
heterogeneity our studies are most likely an underesti-
mation, because we are investigating tissue samples with
a complex composition of single cells. Thus, the genetic
profiles are the sums over all cells contained within the
section and might mask the true tumor heterogeneity.
At the moment we are extending our analysis onto a
single cell level to further gain insight into the evolu-
tionary architecture of prostate tumors. With this we
might be able to pin down the true tumor composition
and we might even identify tumor stem cells on a
genetic level. However, since we find differences
between different biopsies from the same tumor on a
copy number level, we can conclude that several biop-
sies need to be investigated to gain insight into the
genomic context of prostate cancers based the overall
tumor heterogeneity.
Furthermore, with the technologies described we are
now in the progress to extend our analyses to large
sample cohorts from pathology departments where we
can select tissue specimens from specific clinical studies.
This enables us to address clinical relevant questions
such as progression and therapy resistance of tumors
which is an important step towards the application of
targeted re-sequencing approaches as routine diagnostic
tools in oncology.
Conclusion
Illumina sequencing is a powerful tool for large-scale re-
sequencing projects. For clinical applications, in particu-
lar for the benefit of cancer patients, several key issues
need to be addressed: Tissue material, input amounts
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Page 11 of 13and reproducibility of the data in regard to tumor het-
erogeneity. Our optimized protocols guide through each
of these issues and provide data for an optimal strategy
for the usage in clinical settings. We show that FFPE
material can be used with higher coverages as substitu-
tion of cryo-frozen tissue and that it is in particular use-
ful for the determination of germline variations when
tumor tissues have already been sequenced. Lowering
the amount of input material results in an increase of
redundant reads and a slightly higher variance of var-
iant/reference ratios, but can be overcome to a certain
degree with adequate analysis tools. Finally, the tumor
heterogeneity plays an important role for the detection
of copy number variations, but is of minor importance
for the detection of somatic variations. This implies that
the sampling of tumor tissues is of major importance
and needs to be taken into consideration for clinical
diagnostic purposes.
Additional material
Additional file 1: Supplementary Methods, Figure Legends S1-S6,
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